Tonix Pharmaceuticals Holding Corp. (TNXP)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Tonix Pharmaceuticals Holding Corp. (TNXP)
Company Performance

Current Price

as of Oct 16, 2024

$0.16

P/E Ratio

N/A

Market Cap

$21.82M

Description

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Metrics

Overview

  • HQChatham, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerTNXP
  • Price$0.159+12.77%

Trading Information

  • Market Cap$21.82M
  • Float100.00%
  • Average Daily Volume (1m)29,645,219
  • Average Daily Volume (3m)29,053,062
  • EPS-$22.15

Company

  • Revenue$12.46M
  • Rev Growth (1yr)N/A
  • Net Income-$78.78M
  • Gross Margin-107.07%
  • EBITDA Margin-776.90%
  • EBITDA-$17.15M
  • EV$7.95M
  • EV/Revenue0.64
  • P/EN/A
  • P/S0.05
  • P/B0.04
Documents
SEC Filings
8-K (2024-10-17)
8-K (2024-10-16)
8-K (2024-10-08)
8-K (2024-09-27)
8-K (2024-09-23)
8-K (2024-09-19)
8-K (2024-09-16)
8-K (2024-09-10)
8-K (2024-09-09)
8-K (2024-09-06)
8-K (2024-08-30)
8-K (2024-08-29)
8-K (2024-08-26)
8-K (2024-08-20)
8-K (2024-08-19)
8-K (2024-08-12)
8-K (2024-08-09)
8-K (2024-07-30)
8-K (2024-07-25)
8-K (2024-07-16)
8-K (2024-07-10)
8-K (2024-07-08)
8-K (2024-07-01)
8-K (2024-06-28)
8-K (2024-06-26)
8-K (2024-06-20)
8-K (2024-06-13)
8-K (2024-06-10)
8-K (2024-06-06)
8-K (2024-06-03)
8-K (2024-05-30)
8-K (2024-05-22)
8-K (2024-05-21)
8-K (2024-05-13)
8-K (2024-04-01)
8-K (2024-03-29)
8-K (2024-03-25)
8-K (2024-03-21)
8-K (2024-03-20)
8-K (2024-03-19)
8-K (2024-03-11)
8-K (2024-03-07)
8-K (2024-03-06)
8-K (2024-03-05)
8-K (2024-02-28)
8-K (2024-02-27)
8-K (2024-02-15)
8-K (2024-02-13)
8-K (2024-02-12)
8-K (2024-01-31)
8-K (2024-01-29)
8-K (2024-01-25)
8-K (2024-01-19)
8-K (2024-01-08)
8-K (2024-01-02)
8-K (2023-12-21)
8-K (2023-12-20)
8-K (2023-12-12)
8-K (2023-12-08)
8-K (2023-12-04)
8-K (2023-11-15)
8-K (2023-11-13)
8-K (2023-11-09)
8-K (2023-11-02)
8-K (2023-10-31)
8-K (2023-10-30)
8-K (2023-10-26)
8-K (2023-10-20)
8-K (2023-10-19)
8-K (2023-10-18)
8-K (2023-10-16)
8-K (2023-10-04)
8-K (2023-09-29)
8-K (2023-09-27)
8-K (2023-09-25)
8-K (2023-09-21)
8-K (2023-09-18)
8-K (2023-09-14)
8-K (2023-09-11)
8-K (2023-09-06)
8-K (2023-09-05)
8-K (2023-08-21)
8-K (2023-08-16)
8-K (2023-08-10)
8-K (2023-08-07)
8-K (2023-08-01)
8-K (2023-07-31)
8-K (2023-07-28)
8-K (2023-07-27)
8-K (2023-07-26)
8-K (2023-07-24)
8-K (2023-07-17)
8-K (2023-07-12)
8-K (2023-07-10)
8-K (2023-07-03)
8-K (2023-06-26)
8-K (2023-06-15)
8-K (2023-06-13)
8-K (2023-06-07)
8-K (2023-06-05)
8-K (2023-06-01)
8-K (2023-05-31)
8-K (2023-05-25)
8-K (2023-05-23)
8-K (2023-05-22)
8-K (2023-05-17)
8-K (2023-05-09)
8-K (2023-05-08)
8-K (2023-05-05)
8-K (2023-05-04)
8-K (2023-05-01)
8-K (2023-04-19)
8-K (2023-04-17)
8-K (2023-04-13)
8-K (2023-04-06)
8-K (2023-04-05)
8-K (2023-04-04)
8-K (2023-03-30)
8-K (2023-03-23)
8-K (2023-03-20)
8-K (2023-03-16)
8-K (2023-03-13)
8-K (2023-03-07)
8-K (2023-02-27)
8-K (2023-02-23)
8-K (2023-02-13)
8-K (2023-02-09)
8-K (2023-02-07)
8-K (2023-02-06)
8-K (2023-02-02)
8-K (2023-02-01)
8-K (2023-01-31)
8-K (2023-01-30)
8-K (2023-01-26)
8-K (2023-01-25)
8-K (2023-01-24)
8-K (2023-01-10)
8-K (2023-01-04)
10-Q (2024-08-16)
10-Q (2024-05-13)
10-Q (2023-11-09)
10-Q (2023-08-10)
10-Q (2023-05-08)
10-K (2024-04-01)
10-K (2023-03-13)
Factset Street Account
Tonix Pharmaceuticals' TNX-1800 selected by NIH/NIAID project NextGen for inclusion in clinical trials ($0.49, 0.00) (2023-11-02T12:14:09Z)
Tonix Pharmaceuticals reports Q3 EPS ($1.83) vs FactSet ($1.49) [3 est, ($1.66)-(1.17)] ($0.47, 0.00) (2023-11-09T21:42:43Z)
Tonix Pharmaceuticals provides overview of TNX-2900 at the Foundation for Prader-Willi Research Family Conference ($0.56, 0.00) (2023-10-09T11:03:38Z)
Tonix Pharmaceuticals completes clinical stage of Phase 3 RESILIENT study of TNX-102 SL for the management of fibromyalgia ($0.46, 0.00) (2023-11-15T12:10:46Z)
Tonix Pharmaceuticals completes clinical stage of Phase 2 prevention study of TNX-1900 for the prevention of migraine headaches in chronic migraineurs ($0.55, 0.00) (2023-10-26T11:06:45Z)
Tonix Pharmaceuticals announces presentation of new data involving TNX-1500 in heart xenotransplantation in animal models ($0.55, 0.00) (2023-10-30T11:09:58Z)
Tonix Pharmaceuticals announces Enrollment initiated in Mass General Brigham phase 2 study of TNX-1900 for bone health in children with autism spectrum disorder ($0.47, 0.00) (2023-11-13T12:15:30Z)
Tonix announces publication of data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the prevention of rejection in kidney xenotransplantation in animal models ($0.57, 0.00) (2023-10-18T11:06:38Z)